Posted on 10/3/18
Life Biosciences Acquires Lua
Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial . . .
Posted on 10/3/18
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Earlier this year, Bristol-Myers Squibb (NYSE:BMY) made Nektar Therapeutics(NASDAQ:NKTR) a stock market darling by offering billions for rights to an experimental new cancer drug. Recently, a . . .
Posted on 10/3/18
Epizyme Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common . . .
Posted on 10/3/18
Kala Pharmaceuticals Proposes Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that . . .
Posted on 10/3/18
Epizyme Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the pricing of an underwritten public offering of 8,333,334 shares of its . . .
Posted on 10/2/18
FierceBiotech Names Rallybio as One of its “Fierce 15” Biotech Companies of 2018
FARMINGTON, Conn.--(BUSINESS WIRE)--Rallybio, LLC, a development stage biotechnology company, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, . . .
Posted on 10/2/18
Orig3n Announces Collaboration with Researchers at Harvard University
Orig3n, a Boston-based biotech company, today announced a research collaboration agreement with Harvard University, led by a faculty member from the Harvard Stem Cell Institute (HSCI), . . .
Posted on 10/2/18
GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GO Therapeutics, Inc. (GO), a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, today announced that it has entered into a . . .
Posted on 10/2/18
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), . . .
Posted on 10/2/18
FierceBiotech Names Arrakis Therapeutics as One of Its “Fierce 15” Biotech Companies of 2018
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of . . .
Posted on 10/2/18
FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that it has been named . . .
Posted on 10/2/18
FierceBiotech Names Pandion Therapeutics as One of Its “Fierce 15” Biotech Companies of 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics today announced that it has been named by FierceBiotechas one of 2018’s Fierce 15 biotechnology companies, designating it as one of the . . .
Posted on 10/2/18
FierceBiotech Names Kronos Bio As One of Its “Fierce 15” Biotech Companies of 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 . . .
Posted on 10/2/18
FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018
BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the . . .
Posted on 10/2/18
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board . . .
Posted on 10/2/18
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon . . .
Posted on 10/1/18
Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck
Dragonfly Therapeutics, Inc., today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and . . .
Posted on 10/1/18
Protein Dynamic Solutions Recipient of NSF SBIR Phase IIB Supplemental Award
WAKEFIELD, Mass.--(BUSINESS WIRE)--Protein Dynamic Solutions (PDS) was awarded a Small Business Innovation Research (SBIR) Phase IIB grant from the National Science Foundation (NSF) to focus on . . .
Posted on 10/1/18
Boston Biotech Company Partners with Local Luxury Fitness Club
BOSTON--(BUSINESS WIRE)--Ixcela, The Internal FitnessTM Company focusing on gut health and wellness, today announced a collaboration with Lynx Fitness Club that offers members access to Ixcela . . .
Posted on 10/1/18
RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, today announced the . . .
Posted on 10/1/18
Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the completion of its strategic review aimed at reducing costs of . . .
Posted on 10/1/18
EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
WATERTOWN, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced . . .
Posted on 10/1/18
CVS/Aetna: Holding Breath Before The Blessing
SummaryCigna/Express Scripts deal gets approved by DOJ.CVS/Aetna faces regulatory concerns.Linde/Praxair is advancing the asset sale.In this post, you will find a few updates on currently followed . . .
Posted on 9/30/18
Lysogene Provides an Update on Its Financial Communication Agenda
CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, provided today an . . .
Posted on 9/30/18
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine . . .

